Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D.

Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13.

PMID:
30425107
2.

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T.

J Exp Med. 2018 Sep 3;215(9):2325-2337. doi: 10.1084/jem.20180577. Epub 2018 Aug 16.

PMID:
30115740
3.

Cancer immunotherapy: broadening the scope of targetable tumours.

van den Bulk J, Verdegaal EM, de Miranda NF.

Open Biol. 2018 Jun;8(6). pii: 180037. doi: 10.1098/rsob.180037. Review.

4.

The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.

Verdegaal EME, van der Burg SH.

Front Immunol. 2017 Sep 11;8:1113. doi: 10.3389/fimmu.2017.01113. eCollection 2017.

5.

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

Cao J, Brouwer NJ, Richards KE, Marinkovic M, van Duinen S, Hurkmans D, Verdegaal EME, Jordanova ES, Jager MJ.

Oncotarget. 2017 May 20;8(33):54722-54734. doi: 10.18632/oncotarget.18039. eCollection 2017 Aug 15.

6.

IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.

Melief SM, Visser M, van der Burg SH, Verdegaal EME.

Cancer Immunol Immunother. 2017 Jul;66(7):913-926. doi: 10.1007/s00262-017-1995-x. Epub 2017 Apr 11.

7.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM.

Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10.

8.

Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, El Atmioui D, Visser M, Stratton MR, Haanen JB, Spits H, van der Burg SH, Schumacher TN.

Nat Med. 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192d. No abstract available.

PMID:
27711057
9.

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.

van Poelgeest MI, Visconti VV, Aghai Z, van Ham VJ, Heusinkveld M, Zandvliet ML, Valentijn AR, Goedemans R, van der Minne CE, Verdegaal EM, Trimbos JB, van der Burg SH, Welters MJ.

Cancer Immunol Immunother. 2016 Dec;65(12):1451-1463. Epub 2016 Sep 12.

10.

Neoantigen landscape dynamics during human melanoma-T cell interactions.

Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH.

Nature. 2016 Aug 4;536(7614):91-5. Epub 2016 Jun 27.

PMID:
27350335
11.

Adoptive cell therapy: a highly successful individualized therapy for melanoma with great potential for other malignancies.

Verdegaal EM.

Curr Opin Immunol. 2016 Apr;39:90-5. doi: 10.1016/j.coi.2016.01.004. Epub 2016 Jan 30. Review.

12.

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

Vogel CJ, Smit MA, Maddalo G, Possik PA, Sparidans RW, van der Burg SH, Verdegaal EM, Heck AJ, Samatar AA, Beijnen JH, Altelaar AF, Peeper DS.

Pigment Cell Melanoma Res. 2015 May;28(3):307-17. doi: 10.1111/pcmr.12364. Epub 2015 Apr 6.

PMID:
25728708
13.

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, Atmioui DE, Visser M, Stratton MR, Haanen JB, Spits H, van der Burg SH, Schumacher TN.

Nat Med. 2015 Jan;21(1):81-5. doi: 10.1038/nm.3773. Epub 2014 Dec 22. Erratum in: Nat Med. 2016 Oct 6;22(10 ):1192.

PMID:
25531942
14.

Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?

Svane IM, Verdegaal EM.

Cancer Immunol Immunother. 2014 Oct;63(10):1081-91. doi: 10.1007/s00262-014-1580-5. Epub 2014 Aug 7. Review.

PMID:
25099366
15.

Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.

Kaplon J, Hömig-Hölzel C, Gao L, Meissl K, Verdegaal EM, van der Burg SH, van Doorn R, Peeper DS.

Pigment Cell Melanoma Res. 2014 Jul;27(4):640-52. doi: 10.1111/pcmr.12248. Epub 2014 May 14.

PMID:
24703243
16.

Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception?

van Bergen CA, Verdegaal EM, Honders MW, Hoogstraten C, Steijn-van Tol AQ, de Quartel L, de Jong J, Meyering M, Falkenburg JH, Griffioen M, Osanto S.

PLoS One. 2014 Jan 15;9(1):e85198. doi: 10.1371/journal.pone.0085198. eCollection 2014.

17.

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.

Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, Gottlieb E, Peeper DS.

Nature. 2013 Jun 6;498(7452):109-12. doi: 10.1038/nature12154. Epub 2013 May 19.

PMID:
23685455
18.

Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.

Gao L, Smit MA, van den Oord JJ, Goeman JJ, Verdegaal EM, van der Burg SH, Stas M, Beck S, Gruis NA, Tensen CP, Willemze R, Peeper DS, van Doorn R.

Pigment Cell Melanoma Res. 2013 Jul;26(4):542-54. doi: 10.1111/pcmr.12096. Epub 2013 Apr 17.

PMID:
23590314
19.

Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-β.

de Paus RA, van Wengen A, Schmidt I, Visser M, Verdegaal EM, van Dissel JT, van de Vosse E.

Cytokine. 2013 Feb;61(2):645-55. doi: 10.1016/j.cyto.2012.12.005. Epub 2013 Jan 5.

PMID:
23299081
20.

The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.

Singh SK, Tummers B, Schumacher TN, Gomez R, Franken KL, Verdegaal EM, Laske K, Gouttefangeas C, Ottensmeier C, Welters MJ, Britten CM, van der Burg SH.

Cancer Immunol Immunother. 2013 Mar;62(3):489-501. doi: 10.1007/s00262-012-1351-0. Epub 2012 Sep 18.

21.

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.

Verdegaal EM, Visser M, Ramwadhdoebé TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S.

Cancer Immunol Immunother. 2011 Jul;60(7):953-63. doi: 10.1007/s00262-011-1004-8. Epub 2011 Mar 24.

22.

Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target.

Qin Y, Verdegaal EM, Siderius M, Bebelman JP, Smit MJ, Leurs R, Willemze R, Tensen CP, Osanto S.

Pigment Cell Melanoma Res. 2011 Feb;24(1):207-18. doi: 10.1111/j.1755-148X.2010.00781.x. Epub 2010 Oct 21.

PMID:
20880198
23.

Apoptin enhances radiation-induced cell death in poorly responding head and neck squamous cell carcinoma cells.

Schoop RA, Verdegaal EM, Baatenburg de Jong RJ, Noteborn MH.

Basic Clin Pharmacol Toxicol. 2010 Feb;106(2):130-4. doi: 10.1111/j.1742-7843.2009.00482.x. Epub 2009 Oct 27.

24.

Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma.

Verdegaal EM, Hoogstraten C, Sandel MH, Kuppen PJ, Brink AA, Claas FH, Gorsira MC, Graadt van Roggen JF, Osanto S.

Cancer Immunol Immunother. 2007 May;56(5):587-600. Epub 2006 Aug 22.

PMID:
16924494
25.

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.

Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11515-20. Epub 2001 Sep 18.

26.

Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient.

Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S.

Hum Immunol. 1999 Dec;60(12):1195-206.

PMID:
10626733
27.

Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma.

Brouwenstijn N, Hoogstraten C, Verdegaal EM, Van der Spek CW, Deckers JG, Mulder A, Osanto S, Schrier PI.

J Immunother. 1998 Nov;21(6):427-34.

PMID:
9807737
28.

Expression of adhesion molecules on granulocytes and monocytes from patients with asthma stimulated in vitro with interleukin-8 and monocyte chemotactic protein-1.

Verdegaal EM, Zegveld ST, Blokland I, Beekhuizen H, Bakker W, Willems LN, van Furth R.

Inflammation. 1998 Apr;22(2):229-42.

PMID:
9561931
29.
32.

Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.

Los G, Verdegaal EM, Mutsaers PH, McVie JG.

Cancer Chemother Pharmacol. 1991;28(3):159-65.

PMID:
1855272

Supplemental Content

Loading ...
Support Center